Notwithstanding these gains, HER2-positive tumors represent only ~11–15% of breast cancers in the United States, so the remarkable progress with anti-HER2 agents benefits a biologic subset of patients [88,89]. The gene discussed is ERBB2; the disease is breast cancer.